Journal Article

Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes

Li, Ming, Li, Quan, Ishizawa, Kota, Moghal, Nadeem, Cabanero, Michael, Pham, Nhu-An, Huo, Kugeng, Waddell, Thomas K., Martins-Filho, Sebastiao N., Tsao, Ming-Sound, Krieger, Jonathan R., Raghavan, Vibha, Zadeh, Gelareh, Khan, Aafaque A., Agnihotri, Sameer, Mamatjan, Yasin, Shepherd, Frances A., Tong, Jiefei, Taylor, Paul, Tam, Shirley, Liu, Geoffrey, Mirhadi, Shideh, Golbourn, Brian J., Sakashita, Shingo, Weiss, Jessica, Yasufuku, Kazuhiro, Moran, Michael F.

2022

Overview

Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths worldwide. Only a fraction of NSCLC harbor actionable driver mutations and there is an urgent need for patient-derived model systems that will enable the development of new targeted therapies. NSCLC and other cancers display profound proteome remodeling compared to normal tissue that is not predicted by DNA or RNA analyses. Here, we generate 137 NSCLC patient-derived xenografts (PDXs) that recapitulate the histology and molecular features of primary NSCLC. Proteome analysis of the PDX models reveals 3 adenocarcinoma and 2 squamous cell carcinoma proteotypes that are associated with different patient outcomes, protein-phosphotyrosine profiles, signatures of activated pathways and candidate targets, and in adenocarcinoma, stromal immune features. These findings portend proteome-based NSCLC classification and treatment and support the PDX resource as a viable model for the development of new targeted therapies. With non-small cell lung cancer (NSCLC) being the leading cause of cancer deaths worldwide, the development of targeted therapies remains crucial. Here, the generation and multi-omics characterization of 137 NSCLC patient-derived xenografts provides a resource for potential classifications and targets.

• Publisher: Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
• Subject: 38/23 / 38/39 / 631/67/1612/1350 / 631/67/1857 / 64/60 / 82/58 / Adenocarcinoma / Animals / Carcinoma, Non-Small-Cell Lung - pathology / Clinical outcomes / Fatalities / Heterografts / Histology / Humanities and Social Sciences / Humans / Lung cancer / Lung Neoplasms - genetics / Lung Neoplasms - pathology / Mice / Mice, SCID / multidisciplinary / Mutation / Non-small cell lung carcinoma / Patients / Phosphotyrosine / Proteomes / Science / Science (multidisciplinary) / Small cell lung carcinoma / Squamous cell carcinoma / Xenograft Model Antitumor Assays / Xenografts / Xenotransplantation